Bristol’s Integration Strategy With Celgene Includes “Ring-Fencing” Oncology Teams
Executive Summary
Firm hopes to minimize merger disruption by maintaining separate BMS, Celgene cancer expertise. Opdivo posts solid growth, but longer-term worries persist.